Cerebain Biotech Has Made a Capital Investment in Diabetes Reversal Group, LLC
29 Sep 2022
Sept. 29, 2022 12:30 UTC
COSTA MESA, Calif.--(BUSINESS WIRE)-- Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) today announced that it has made a capital investment in Diabetes Reversal Group, LLC.
“Cerebain is happy to announce it has made a capital investment in Diabetes Reversal Group, LLC (DRG). We are confident in the growth potential of DRG due to the size of the diabetes market and the demand for ways to reverse this epidemic disease,” says Eric Clemons, CEO of Cerebain.
DRG has the only patented system in the world that reverses Type 2 Diabetes, and they guarantee results. They have a 13-year track record and have helped thousands of diabetics reverse their disease once and for all and get off their medications.
“We are excited to expand nationally and internationally with our incredible program, so we can help diabetics reverse this disease that causes so many devastating complications,” says Kristine Burke, MD, who is triple board certified and the Chief Medical Officer of DRG.
About Cerebain Biotech Corp.
Cerebain Biotech Corp. is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at or connect with us on Twitter and Facebook to learn more.
About Diabetes Reversal Group, LLC
Diabetes Reversal Group, LLC was founded to provide a natural diabetes treatment, non-drug approach to helping people with metabolic and nutritional imbalances. These imbalances can lead to many health problems traditionally treated with invasive prescription drug therapy, such as Type 2 Diabetes, Neuropathy and Heart Disease. The Patented program developed by DRG helps Type 2 Diabetes, Neuropathy and Heart Disease by restoring proper metabolic function and nutritional balance. We have seen remarkable results with the improvement or elimination of these conditions, working in conjunction with your primary physician. Visit us at .
Forward Looking Statements
This news release contains certain "forward- looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.